Pacritinib vs Ruxolitinib
Ruben A. Mesa, MD, chair, Hematology, deputy director, Mayo Clinic, discusses pacritinib vs ruxolitinib.
Mesa speaks about a study that used pacritinib, instead of ruxolitinib. This drug was not chosen for this study because ruxolitinib was not indicated for patients with a platelet count under 100,000, when the trial began.
Mesa explains the difficulty of comparing data from the two drugs, but he was able to say that there are many vital benefits for splenomegaly symptoms that were presented in both phase III studies.
Ruben A. Mesa, MD, chair, Hematology, deputy director, Mayo Clinic, discusses pacritinib vs ruxolitinib.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
